Notable healthcare headlines for the week: Walgreens Boots Alliance, AbbVie and Novo Nordisk in focus
Wall Street's major averages dipped for the week as investors wrestled with tariff twists from the Trump administration. The ...
Shocking stories of people who went blind after taking Ozempic and Mounjaro
Weight loss drugs like Ozempic, while transformative in combating obesity, have been linked to irreversible vision impairment ...
UBS highlights five long-term themes for investors to consider
An increasing share of the population is living in retirement for longer periods of time, offering "specific market ...
Top Growth Stocks To Follow Now – March 7th
Blackstone, BlackRock, Apollo Global Management, Novo Nordisk A/S, Welltower, Prologis, and Venture Global are the seven Growth stocks to watch today, according to MarketBeat’s stock screener tool.
Hikma races to launch generic versions of blockbuster obesity drugs
Hikma launched liraglutide, a generic version of an earlier Novo Nordisk weight loss drug, in the US in December. Liraglutide, which Novo sells as Victoza for diabetes and Saxenda for weight loss, has ...
Ozempic maker says its Australian market could be half the population
Novo Nordisk says many Australians would be willing to pay the out-of-pocket costs for its blockbuster medicines, which can ...